Open-label assessment shows the long-term efficacy and safety of risankizumab in Crohn's disease patients, indicating its potential for sustained management.
Background: Part 2 of the SEQUENCE study examines the long-term efficacy and safety of risankizumab (RZB), an IL-23 p19 inhibitor, in patients (pts) with moderate to severe Crohn's disease (CD). We report the 1-year results from part 2 of the SEQUENCE study.
No takes yet. Share an insight, caveat, or question.
Peyrin‐Biroulet et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: